Entity

Time filter

Source Type

Verdun, Canada

Chen Y.,University of North Carolina at Chapel Hill | Wu J.J.,Ambrilia Biopharma Inc. | Huang L.,University of North Carolina at Chapel Hill
Molecular Therapy | Year: 2010

We have designed a PEGylated LPD (liposome-polycation-DNA) nanoparticle for systemic, specific, and efficient delivery of small interfering RNA (siRNA) into solid tumors in mice by modification with NGR (aspargine-glycine-arginine) peptide, targeting aminopeptidase N (CD13) expressed in the tumor cells or tumor vascular endothelium. LPD-PEG-NGR efficiently delivered siRNA to the cytoplasm and downregulated the target gene in the HT-1080 cells but not CD13 HT-29 cells, whereas nanoparticles containing a control peptide, LPD-PEG-ARA, showed only little siRNA uptake and gene silencing activity. LPD-PEG-NGR efficiently delivered siRNA into the cytoplasm of HT-1080 xenograft tumor 4 hours after intravenous injection. Three daily injections (1.2mg/kg) of c-myc siRNA formulated in the LPD-PEG-NGR effectively suppressed c-myc expression and triggered cellular apoptosis in the tumor, resulting in a partial tumor growth inhibition. When doxorubicin (DOX) and siRNA were co-formulated in LPD-PEG-NGR, an enhanced therapeutic effect was observed. © The American Society of Gene and Cell Therapy. Source


Trademark
Ambrilia Biopharma Inc. | Date: 2006-04-07

Pharmaceutical preparations for the treatment of cancer and infectious diseases. Manufacturing services for others in the field of therapeutic and diagnostic products. Pharmaceutical research and development in the field of therapeutic and diagnostic products.


Trademark
Ambrilia Biopharma Inc. and Procyon Biopharma Inc. | Date: 2002-08-27

TOPICAL CREAM TO INHIBIT HYPERTROPHIC SCARRING.


Trademark
Ambrilia Biopharma Inc. | Date: 2005-12-08

Pharmaceutical preparations for the treatment of cancer and infectious diseases. Manufacturing services for others in the field of therapeutic and diagnostic products. Pharmaceutical research and development in the field of therapeutic and diagnostic products.


Trademark
Ambrilia Biopharma Inc. and Procyon Biopharma Inc. | Date: 2005-11-22

Pharmaceutical preparations. Research and development relating to biotechnological and pharmaceutical products and services; production of pharmaceutical products to customer specifications; operation of a business selling biological and pharmaceutical products including diagnostic reagents, kits and therapeutic agents.

Discover hidden collaborations